The U.S. Food and Drug Administration has approved CV Therapeutics’ Ranexa (ranolazine) for treating chronic angina. The changed labeling also informs that Ranexa showed better results for conditions like arrhythmias, new onset atrial fibrillation and bradycardia (dangerously slow heartbeat in patients of coronary artery disease). Also, the labeling mentions that Ranexa lowers hemoglobin A1c (HbA1c) in diabetes patients. The drug can now be used as a part of optimal therapy. Neither it reduces heart rate nor blood pressure. Unlike other long acting nitrates, Ranexa is prescribed for patients taking oral treatments for erectile dysfunction.